16/04/2021

PhD position

This job offer has expired


  • ORGANISATION/COMPANY
    Lausanne University Hospital and University of Lausanne
  • RESEARCH FIELD
    Biological sciencesOther
  • RESEARCHER PROFILE
    First Stage Researcher (R1)
  • APPLICATION DEADLINE
    16/05/2021 21:00 - Europe/Athens
  • LOCATION
    Switzerland › Epalinges
  • TYPE OF CONTRACT
    To be defined
  • JOB STATUS
    Full-time
  • HOURS PER WEEK
    42
  • OFFER STARTING DATE
    01/06/2021

OFFER DESCRIPTION

Targeting Pathway Vulnerabilities Induced by Epigenetic Disturbance in Glioblastoma

The laboratory works at the interphase of basic and clinical research in brain tumors. In the proposed project, we aim at identifying druggable vulnerabilities of cancer relevant pathways revealed upon disturbing the tumor cells by epigenetic drugs, such as Bromodomain inhibitors (BETi). BETi target chromatin readers such as BRD4 that regulate expression of proto-oncogenic genes. We have identified several gene signatures indicative of cancer relevant pathways that are disturbed upon treatment with BETi. Investigating the function of these genes/pathways mechanistically in in vitro models and with bio-informatics approaches, will inform on their suitability to serve, as targets for treatment and the biological function will guide the choice for the second drug to use. Hits will be tested for synergistic effects with BET inhibition. Successful combinations will be taken into patient derived orthotopic xenograft models in the mouse. Molecular biomarkers and magnetic resonance imaging/ spectroscopy based response markers will be developed for translation into the clinical setting. 1,2 3

References:

1. Gusyatiner O, Hegi ME. Glioma epigenetics: From subclassification to novel treatment options. Semin Cancer Biol. 2018; 51:50-58.

2. Gusyatiner O, Pham MDT, Lei Y, et al. BET inhibitors synergize with HDAC inhibitors and downregulate expression of interferon response genes in glioblastoma. In: AACR, ed. 109th Annual Meeting of the American Association for Cancer Research, Abstr #2923. Vol 78. Chicago, Illinois: AACR; 2018.

3. Stathis A, Bertoni F. BET proteins as targets for anticancer treatment. Cancer Discov. 2018; 8(1):24-36.

More Information

Benefits

  • PhD program Immunology and Cancer of the University of Lausanne (upon successful selection)
  • Participation in programs of the Swiss Cancer Center Léman

Eligibility criteria

 

 

 

Selection process

Complete CV

Name  & email of 2  referees

 

 

Offer Requirements

  • REQUIRED EDUCATION LEVEL
    Biological sciences: Master Degree or equivalent

Skills/Qualifications

We are looking for a highly motivated student with interest in cancer biology and genetics who would like to make a difference

 

  • Basic molecular biology techniques, (quantitative PCR, Western, etc)
  • Cell culture
  • Basic skills and interest in bioinformatics (R statistic language)
  • Willingness to work with animals (mice)
  • Team player for collaborative projects

Work location(s)
1 position(s) available at
Lausanne University Hospital and University of Lausanne
Switzerland
Choose One...
Epalinges
1066
ch des Boveresses 155

EURAXESS offer ID: 629848

Disclaimer:

The responsibility for the jobs published on this website, including the job description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.

 

Please contact support@euraxess.org if you wish to download all jobs in XML.